ADVERTISEMENT

Market Access

A Passport To Streamlined Medtech Access Under UK Life Sciences Plan

An “NHS Innovator Passport” that allows quicker uptake of proven technologies across the national healthcare provider is one of the wins the UK government is looking to score from its new Life Sciences Sector plan. The plan majors on prevention. The medtech industry has given it a cautious welcome.

ViiV Extends Voluntary License For Long-Acting Cabotegravir As HIV Treatment

The Medicines Patent Pool’s extended voluntary license to produce long-acting cabotegravir to treat HIV is a win for patients living in LMICs, as the WHO updated its guidance to recommend it as an alternative treatment option.

Hopes Rise For Sickle Cell Gene Therapy Access As 33 States Join CMS Program

CMS said that 33 US states plus the District of Columbia and Puerto Rico had joined a program whereby the agency negotiates outcomes-based contracts on their behalf.

Making The UK A Leading Biosimilar Launch Destination – Realistic Or Optimistic?

Experts discussed the UK government’s commitment to make the country a desirable destination for companies to launch their biosimilars at a recent conference hosted by Medicines UK.

Wave of Biopharma Licensing Deals in India: ‘The Model Is Working’

From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.

Industry Criticizes Dutch Decision To Slash PARP Inhibitor Reimbursement

ZIN, the Dutch health technology assessment body, estimates that the number of patients eligible for treatment with a PARP inhibitor will be halved following a reassessment of drugs in the class.

Watch This Space: Miltenyi‘s ‘Brain-To-Vein,’ Point-Of-Care CAR-T Efforts In India

From a letter of intent with BIRAC sealed at BIO 2025 to supporting Immuneel’s CAR-T efforts and a study for point-of-care manufactured anti-CD19 CAR-T cell therapy, Miltenyi Biotec is moving on multiple fronts in India. The German group also expects to advance its own CAR-T candidates.

How Will Regulatory Filing Winds Blow Globally For Elevidys Following Patient Deaths?

Roche’s filing for Elevidys in the EU followed applications in Middle Eastern countries because those markets accept applications based on approval by the US Food and Drugs Administration.

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut

Denmark Introduces First Confidential Pricing Framework For Primary Care Medicines

Expanded confidential pricing for pharmaceuticals is intended to help manage medicines expenditure, according to Amgros, the procurement agency that will negotiate the prices.

Mexico’s New Procurement Rules Aim To Increase Healthcare Investment, But May Face Legal Trouble

Legal experts warn, however, that new Mexican procurement rules are discriminatory and could be challenged in the courts.

New Drug Procurement Rules Aim To Drive Pharma Investment In Mexico

Legal experts warn, however, that new Mexican procurement rules are discriminatory and could be challenged in the courts.